The occurrence of adverse events after presentation with acute coronary syndromes is affected by multiple factors. These factors should be considered in the clinical decision-making process.
Background: Despite clear evidence for the efficacy of lowering cholesterol levels, there is a deficiency in its realworld application. There is a need to explore alternative strategies to address this important public health problem. This study aimed to determine the effect of a program of community pharmacist intervention on the process of cholesterol risk management in patients at high risk for cardiovascular events.
Summary
Background
In Africa, up to 30% of HIV-infected patients who are
clinically eligible for antiretroviral therapy (ART) do not start timely
treatment. We assessed the effects of an intervention targeting prevalent
health systems barriers to ART initiation on timing and completeness of
treatment initiation.
Methods
In this stepped-wedge, non-blinded, cluster-randomised controlled
trial, 20 clinics in southwestern Uganda were randomly assigned in groups of
five clinics every 6 months to the intervention by a computerised random
number generator. This procedure continued until all clinics had crossed
over from control (standard of care) to the intervention, which consisted of
opinion-leader-led training and coaching of front-line health workers, a
point-of-care CD4 cell count testing platform, a revised counselling
approach without mandatory multiple pre-initiation sessions, and feedback to
the facilities on their ART initiation rates and how they compared with
other facilities. Treatment-naive, HIV-infected adults (aged ≥18
years) who were clinically eligible for ART during the study period were
included in the study population. The primary outcome was ART initiation 14
days after first clinical eligibility for ART. This study is registered with
ClinicalTrials.gov, number NCT01810289.
Findings
Between April 11, 2013, and Feb 2, 2015, 12 024 eligible patients
visited one of the 20 participating clinics. Median CD4 count was 310 cells
per μL (IQR 179–424). 3753 of 4747 patients (weighted
proportion 80%) in the intervention group had started ART by 2 weeks
after eligibility compared with 2585 of 7066 patients (38%) in the
control group (risk difference 41·9%, 95% CI
40·1–43·8). Vital status was ascertained in a random
sample of 208 patients in the intervention group and 199 patients in the
control group. Four deaths (2%) occurred in the intervention group
and five (3%) occurred in the control group.
Interpretation
A multicomponent intervention targeting health-care worker behaviour
increased the probability of ART initiation 14 days after eligibility. This
intervention consists of widely accessible components and has been tested in
a real-world setting, and is therefore well positioned for use at scale.
Funding
National Institute of Allergy and Infectious Diseases (NIAID) and the
President’s Emergency Fund for AIDS Relief (PEPFAR).
SCRIP (Study of Cardiovascular Risk Intervention by Pharmacists) is a unique ongoing trial that is evaluating a community pharmacist intervention designed to optimize cholesterol risk management in patients at high risk for cardiovascular events.
Key Points
Question
How is the demand for HIV self-testing influenced by pricing and distribution strategies?
Findings
In a randomized clinical trial of 4000 adults in Zimbabwe, demand for HIV self-testing declined substantially from 32.5% among those offered self-administered tests for free to 6.9% among those offered the tests for US $0.50 and below 3% at prices of US $1 or greater. Price sensitivity was higher among rural residents, men, and those who had never had an HIV test; in urban areas, demand was higher with pharmacy- than clinic-based distribution.
Meaning
This study suggests that demand for HIV self-testing is highly price sensitive in low-income settings; free distribution of self-tests may help promote their use in high-priority population segments.
Background
In 2013-14, we achieved 89% adult HIV testing coverage using a hybrid testing approach in 32 communities in Uganda and Kenya (SEARCH: NCT01864603). To inform scalability, we sought to determine: 1) overall cost and efficiency of this approach; and 2) costs associated with point-of-care (POC) CD4 testing, multi-disease services, and community mobilization.
Methods
We applied micro-costing methods to estimate costs of population-wide HIV testing in 12 SEARCH Trial communities. Main intervention components of the hybrid approach are census, multi-disease community health campaigns (CHC), and home-based testing (HBT) for CHC non-attendees. POC CD4 tests were provided for all HIV-infected participants. Data were extracted from expenditure records, activity registers, staff interviews, and time and motion logs.
Results
The mean cost per adult tested for HIV was $20.5 (range: $17.1 - $32.1) [2014 US$], including a POC CD4 test at $16 per HIV+ person identified. Cost per adult tested for HIV was $13.8 at CHC vs. $31.7 via HBT. The cost per HIV+ adult identified was $231 ($87 - $1,245), with variability due mainly to HIV prevalence among persons tested (i.e., HIV positivity rate). The marginal costs of multi-disease testing at CHCs were $1.16/person for hypertension and diabetes, and $0.90 for malaria. Community mobilization constituted 15.3% of total costs.
Conclusions
The hybrid testing approach achieved very high HIV testing coverage, with POC CD4, at costs similar to previously reported mobile, home-based, or venue-based HIV testing approaches in sub-Saharan Africa. By leveraging HIV infrastructure, multi-disease services were offered at low marginal costs.
Background-In a previous substudy of the GUSTO-I trial, we observed better functional and quality-of-life outcomes among patients in the United States (US patients) compared with patients in Canada. Rates of invasive therapy were significantly higher in the United States and were associated with a small mortality benefit (0.4%, adjusted Pϭ0.02). We sought to determine whether Canadian-US differences in practice patterns in GUSTO-I had an impact on 5-year mortality. Methods and Results-Mortality data for 23 105 US and 2898 Canadian patients enrolled in GUSTO-I were obtained from national mortality databases. Median follow-up was 5.46 years in the US and 5.33 years in the Canadian cohort. Five-year mortality rate was 19.6% among US and 21.4% among Canadian patients (Pϭ0.02). After baseline adjustment, enrollment in Canada was associated with a higher hazard of death (1.17; 95% confidence interval, 1.07 to 1.28, Pϭ0.001). Revascularization rates during the index hospitalization in the United States were almost 3 times those in Canada: 30.5% versus 11.4% for angioplasty and 13.1% versus 4.0% for bypass surgery (PϽ0.01 for both). After accounting for revascularization status as a time-dependent covariate, country was no longer a significant predictor of long-term mortality. These results were confirmed in a propensity-matched analysis. Conclusions-Our results suggest, for the first time, that the more conservative pattern of care with regard to early revascularization in Canada for ST-segment elevation acute myocardial infarction may have a detrimental effect on long-term survival. Our results have important policy implications for cardiac care in countries and healthcare systems wherein use of invasive procedures is similarly conservative.
Use of evidence-based therapies for management of ACS patients is strongly associated with region. To improve patient outcomes, more research is needed to understand this variation, and to institute appropriate solutions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.